Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Sickle Cell Disease
NCT03279094Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Feb 2018
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Stem Cell Therapies, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Hematopoietic Stem Cell Transplantation (Medical College of Wisconsin) in sickle cell disease (SCD), sponsored by City of Hope. Primary endpoint: Rate of unacceptable adverse events at 190 days. Planned start Feb 2018; status: withdrawn.
02
Drugs
Hematopoietic Stem Cell Transplantation (Medical College of Wisconsin)
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03279094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279094.